Evidence map›Paper›PMID 23311763›Full record

ArticleInternational archives of medicine2013

Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer.

Ricardo Moreno, Pamela O Delgado, Patrícia G Coelho, Sarah R Marsicano, Viviane Av Boas, Ligia A Azzalis, Virgínia Bc Junqueira, Katya C Rocha, Luiz Carlos de Abreu, Vitor E Valenti and 3 more

Open access · diamondAbstract read
In one paragraph

Article in International archives of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ricardo MorenoLaboratório de Análises Clínicas, Faculdade de Medicina do ABC, Av, Príncipe de Gales 821, Santo André, CEP: 09060-650, Brazil. fon_fonseca@yahoo.com.br.
Pamela O Delgado
Patrícia G Coelho
Sarah R Marsicano
Viviane Av Boas
Ligia A Azzalis
Virgínia Bc Junqueira
Katya C Rocha
Luiz Carlos de Abreu
Vitor E Valenti
Jefferson Drezzet
Edimar Cristiano Pereira
Fernando L Fonseca
Faculdade de Medicina do ABC · BRUniversidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral studies seek biological markers that give diagnostic and degree of tumor development. The aim of this study was to validate the determination of plasma DNA using nanotechnology (Nanovue™-NV) in samples of 80 patients with prostate cancer.

methodsBlood samples of 80 patients of the Urology Ambulatory of Faculdade de Medicina do ABC with prostate cancer confirmed by anatomical-pathology criteria were analyzed. DNA extraction was performed using a GFX TM kit (Amersham Pharmacia Biotech, Inc, USA) following the adapted protocol. Plasma was subjected to centrifugation.

resultsThere was a big difference between the first and the second value obtained by NanoVue Only two samples had no differences between duplicates. Maximum difference between duplicates was 38 μg/mL. Average variation between 51 samples was 10.29 μg/mL, although 21 samples had differences above this average. No correlation was observed between pDNA obtained by traditional spectrophotometry and by nanotechnology.

conclusionDetermination of plasma DNA by nanotechnology was not reproducible.

Identifiers

PMID23311763
PMCPMC3605229
OpenAlexW2157766747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.